A CRISPR edit for heart disease

King, Anthony

doi:10.1038/d41586-018-02482-4

Cited by 16 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Para Hiro Nakauchi, de la Universidad de Stanford, en 5 a 10 años pueden empezar a darse este 13 "In our view, genome editing in human embryos using current technologies could have unpredictable effects on future generations. is makes it dangerous and ethically unacceptable.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

El Derecho ante la técnica de edición genética CRISPR

Krenz

2019

Acta bioeth.

View full text Add to dashboard Cite

Resumen: La técnica de edición genética CRISPR constituye uno de los avances recientes más extraordinarios en materia de biotecnología, de alcances insospechados. En ese contexto, resulta fundamental analizar sus repercusiones en el ámbito de los derechos humanos, toda vez que, así como puede propiciar avances extraordinarios para su mejor desarrollo, puede también generar nuevas amenazas.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Esto lo hace peligroso y éticamente inaceptable. Tal investigación podría ser empleada para producir modificaciones no terapéuticas", entre otras consideraciones 13 .…”

Section: Discussionunclassified

El Derecho ante la técnica de edición genética CRISPR

Krenz

2019

Acta bioeth.

View full text Add to dashboard Cite

show abstract

“…Consequently, this axis is proposed as a therapeutic target against heart failure, ischemia, and other diseases as discussed earlier. In recent years, CRISPR (clustered regularly interspaced short palindromic repeats) has been successfully implemented in various applications including the editing of epigenetic factors [ 190 , 191 ] and as a potential option to address heart disease [ 192 ]. Based on the success of CRISPR, it is not surprising that CRISPR has been used to detect SARS-CoV-2 [ 193 , 194 ] and the advantages of CRISPR in various aspects of COVID-19 treatment are being considered [ 195 , 196 ].…”

Section: Discussionmentioning

confidence: 99%

Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19

Sarkar

Sen

2022

Epigenomes

View full text Add to dashboard Cite

Although few in number, studies on epigenome of the heart of COVID-19 patients show that epigenetic signatures such as DNA methylation are significantly altered, leading to changes in expression of several genes. It contributes to pathogenic cardiac phenotypes of COVID-19, e.g., low heart rate, myocardial edema, and myofibrillar disarray. DNA methylation studies reveal changes which likely contribute to cardiac disease through unknown mechanisms. The incidence of severe COVID-19 disease, including hospitalization, requiring respiratory support, morbidity, and mortality, is disproportionately higher in individuals with co-morbidities. This poses unprecedented strains on the global healthcare system. While their underlying conditions make patients more susceptible to severe COVID-19 disease, strained healthcare systems, lack of adequate support, or sedentary lifestyles from ongoing lockdowns have proved detrimental to their underlying health conditions, thus pushing them to severe risk of congenital heart disease (CHD) itself. Prophylactic vaccines against COVID-19 have ushered new hope for CHD. A common connection between COVID-19 and CHD is SARS-CoV-2’s host receptor ACE2, because ACE2 regulates and protects organs, including the heart, in various ways. ACE2 is a common therapeutic target against cardiovascular disease and COVID-19 which damages organs. Hence, this review explores the above regarding CHDs, cardiovascular damage, and cardiac epigenetics, in COVID-19 patients.

show abstract

“…Additionally, several primary prevention treatments are under investigation to reduce CVD risk including metformin, 3, 4 low-dose aspirin, 5 and gene therapy. 6 Given the costs and risks associated with these treatments, targeting them to the most at-risk patients will be important.…”

Section: Purposementioning

confidence: 99%

Cardiovascular disease and all-cause mortality risk prediction from abdominal CT using deep learning

Elton

Chen

Pickhardt

et al. 2021

Preprint

View full text Add to dashboard Cite

Cardiovascular disease is the number one cause of mortality worldwide. Risk prediction can help incentivize lifestyle changes and inform targeted preventative treatment. In this work we explore utilizing a convolutional neural network (CNN) to predict cardiovascular disease risk from abdominal CT scans taken for routine CT colonography in otherwise healthy patients aged 50-65. We find that adding a variational autoencoder (VAE) to the CNN classifier improves its accuracy for five year survival prediction (AUC 0.787 vs. 0.768). In four-fold cross validation we obtain an average AUC of 0.787 for predicting five year survival and an AUC of 0.767 for predicting cardiovascular disease. For five year survival prediction our model is significantly better than the Framingham Risk Score (AUC 0.688) and of nearly equivalent performance to method demonstrated in Pickhardt et al. (AUC 0.789) which utilized a combination of five CT derived biomarkers.

show abstract

A CRISPR edit for heart disease

Abstract: Advances in gene editing raise the prospect of a one-off injection that could reduce the risk of cardiovascular disease.Kiran Musunuru (centre) and his team are using genome editing in the mouse liver to modify enzymes that regulate levels of 'bad' cholesterol.

Cited by 16 publications

References 15 publications

El Derecho ante la técnica de edición genética CRISPR

El Derecho ante la técnica de edición genética CRISPR

Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19

Cardiovascular disease and all-cause mortality risk prediction from abdominal CT using deep learning

Contact Info

Product

Resources

About